New drug combo targets Hard-to-Treat cancers with KRAS mutation
NCT ID NCT06166836
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults whose cancer has worsened after standard treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
D-1553 (a KRAS G12C inhibitor) and IN10018 (a focal adhesion kinase inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have a specific KRAS G12C mutation.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants. The combination may not work better than existing treatments, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Bengbu Medical College
Bengbu, China
-
First Affiliated Hospital of Gannan Medical University
Ganzhou, China
-
Fujian Cancer Hospital
Fuzhou, China
-
General Hospital Of Eastern Theater Command
Nanjing, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Hunan Cancer Hospital
Changsha, China
-
Renmin Hospital of Wuhan University
Wuhan, China
-
The first Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
Xuzhou Central Hospital
Xuzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China